dihydroergotamine mesylate · Amneal · NDA 215400

Brekiya (Autoinjector)

Earliest generic entry, as listed
24 Aug 2039

Blocked by patent: US 12414941.

Listed patents · 8 unexpired

11 Orange Book listing rows for 8 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.

PatentClaimsExpires
US 12414941drug product · sets the listed date24 Aug 2039
US 11083712drug product, use U-2718, U-450830 Jun 2039
US 11083712 listing rowdrug product, use U-271830 Jun 2039
US 11083712 listing rowdrug product, use U-450830 Jun 2039
US 12329749drug product, use U-2718, U-450827 May 2039
US 12329749 listing rowdrug product, use U-271827 May 2039
US 12329749 listing rowdrug product, use U-450827 May 2039
US 11541043drug product20 Mar 2039
US 10532049drug product26 Feb 2039
US 11304942drug product26 Feb 2039
US 11819501use U-4188, U-84826 Feb 2039
US 11819501 listing rowuse U-418826 Feb 2039
US 11819501 listing rowuse U-84826 Feb 2039
US 12533351drug product26 Feb 2039

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
215400 · 001 · RLDsolution, subcutaneous1MG/ML24 Aug 2039